Melanocortin Pathway and Libido: Bremelanotide / PT-141 and Melanotan II

Status: draft (compiled 2026-04-28)

The melanocortin axis is the strangest pharmacological route into human libido that the modern drug market has bothered to chart, and it earns that strangeness honestly. Most agents that touch sexual function do so peripherally: PDE5 inhibitors block phosphodiesterase isoenzyme 5 in cavernosal smooth muscle and let nitric-oxide signalling extend a vascular response that has already been initiated by desire and tactile stimulation, while testosterone replacement works at long timescales on hormonal substrate. Melanocortin agonists do something different. They act centrally, in hypothalamic and limbic circuitry that gates sexual motivation rather than sexual hardware, and they share that machinery with skin pigmentation, appetite, energy expenditure, and thermoregulation. The clinical drug that came out of this pathway is bremelanotide, sold in the United States as Vyleesi, and the gray-market peptide that preceded it and still feeds online tanning subcultures is Melanotan II. The two compounds are close structural relatives, but they are not interchangeable, and the regulatory and safety distance between them is much larger than the chemistry suggests. Understanding why requires a careful reading of the FDA label, the RECONNECT trials, the original University of Arizona work that produced both peptides, and the case-report literature that has accumulated around unregulated melanocortin agonist use. Sources: Vyleesi prescribing information at DailyMed, Bremelanotide first approval, Drugs 2019, PMID 31429064, Hadley & Dorr 2006 review, PMID 16412534. Confidence: C1 for the regulatory and pharmacological framing.

The discovery story is not lore. It is well documented in the University of Arizona's own publications and in the Hadley and Dorr 2006 melanocortin therapeutics review. Mac Hadley and Victor Hruby's group at Arizona spent the 1980s engineering metabolically stable analogs of α-melanocyte-stimulating hormone, the natural pituitary heptadecapeptide that activates melanocortin receptors. Their goal was photoprotective tanning rather than libido: a synthetic agonist of the cutaneous MC1 receptor that would drive eumelanin production without UV damage, with possible relevance to xeroderma pigmentosum and similar conditions. The lead compound was Melanotan II, a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂, in which a lactam bridge between the Asp and Lys side chains constrains the ring into a bioactive geometry that resembles α-MSH but resists peptidase degradation. The substitution of norleucine for methionine at position 4 prevents oxidation, and the D-phenylalanine at position 7 blocks proteolysis. What the early Arizona phase-I dosing trials actually showed was that healthy male volunteers receiving subcutaneous MT-II reported spontaneous, unstimulated penile erections, often accompanied by yawning and nausea. That observation, repeated across early human work, is the seed from which the entire melanocortin libido program grew. Sources: Hadley & Dorr 2006, PMID 16412534, King et al. 2005 discovery review, PMID 15996790, Wessells 1998 J Urol, PMID 9679884. Confidence: C2 for the structural details and historical sequence.

Wessells, Levine, Hadley and colleagues then formalized that incidental finding in two small but consequential trials. The 1998 Journal of Urology paper enrolled ten men with psychogenic erectile dysfunction in a double-blind, placebo-controlled crossover study at 0.025 mg/kg subcutaneous Melanotan II, with RigiScan monitoring over six hours. Eight of ten developed clinically apparent erections, with mean tip-rigidity-greater-than-80% duration of 38 minutes on MT-II versus 3 minutes on placebo (p = 0.0045), and side effects were limited to transient nausea, stretching, and yawning. The 2000 International Journal of Impotence Research paper extended the work to a broader 20-man mixed psychogenic-and-organic ED population and added a sexual desire questionnaire: 17 of 20 men erected without sexual stimulation, mean rigidity-over-80% time was about 41 minutes, and increased sexual desire was reported after 13 of 19 (68%) MT-II doses versus 4 of 21 (19%) placebo doses, p < 0.01. A companion Urology report in 2000 confirmed similar findings in organic ED. These are tiny studies by modern phase-3 standards, and severe nausea was reported in roughly 12.9% of subjects at the 0.025 mg/kg dose, but the libido signal was unmistakable: this was a centrally acting compound, not a vascular one, and it had effects on motivation that PDE5 inhibitors could not replicate. Sources: Wessells 1998 J Urol, PMID 9679884, Wessells 2000 IJIR, PMID 11035391, Wessells 2000 Urology, PMID 11018622. Confidence: C1 for the trial outcomes; C2 for the framing.

Palatin Technologies then took the engineering problem one step further. MT-II was attractive as a tanning agent and as a libido proof-of-concept, but it was a non-selective melanocortin agonist that hit MC1R, MC3R, MC4R, and MC5R at sub-nanomolar to nanomolar affinities, which meant the same molecule that increased sexual desire also drove cutaneous melanogenesis, gastrointestinal side effects, and a basket of other receptor-mediated consequences. The strategy that produced PT-141, later named bremelanotide, was to keep the cyclic-lactam α-MSH-mimetic scaffold but trim the C-terminal amide to a free carboxylic acid (the change that distinguishes Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH from the parent MT-II amide). Bremelanotide is in fact described by multiple sources as an active C-terminal-modified metabolite of MT-II. The intended pharmacology was a shift in the receptor potency order toward central MC4R/MC3R agonism and away from cutaneous MC1R activity. The actual, label-confirmed potency order at the four bound receptors in vitro is MC1R, MC4R, MC3R, MC5R, MC2R, which means that bremelanotide is still ranked highest at MC1R when ordered by potency at each receptor type. The clinically relevant point is that the absolute MC1R activity is much lower than MT-II's, but it is not zero, and that residual MC1R activity is precisely why focal hyperpigmentation appears on the FDA label rather than disappearing with the structural redesign. The user's draft framing that hyperpigmentation occurs "for interesting reasons" is correct: the molecule is structurally a constrained α-MSH analog acting on the same melanocyte receptor that endogenous α-MSH uses to drive eumelanin synthesis, and dose-frequency exposure determines whether that residual activity becomes visible. Sources: Vyleesi prescribing information at DailyMed, Bremelanotide Wikipedia structural summary, Pfaus et al. 2003 PT-141 review, PMID 12851303. Confidence: C1 for the receptor-order ranking from the label; C2 for the structural lineage detail.

The central mechanism by which MC4R activation alters sexual motivation is still incompletely characterized, but the broad outlines are now reasonably stable in the primary literature. Bremelanotide's neurobiology review (Pfaus and colleagues) and the broader rodent and human work converge on a model in which MC4 receptors in the medial preoptic area, paraventricular nucleus, ventral tegmental area, nucleus accumbens, and amygdala mediate effects on dopaminergic and oxytocinergic outflow that bias the brain toward appetitive sexual behaviour. The exact label language is more conservative: the FDA writes that "the mechanism by which Vyleesi improves HSDD is unknown," which is the correct epistemic position even though the receptor target is well established. This matters because melanocortin libido enhancement is fundamentally a desire/motivation drug rather than a peripheral arousal drug, and the framing of "central libido pathway" that some clinical writeups use is appropriate as long as one keeps the MOA-unknown caveat attached. Sources: Bremelanotide neurobiology review, Pfaus 2021, PMID 33455598, Pfaus PT-141 review 2003, PMID 12851303, Vyleesi prescribing information at DailyMed. Confidence: C2 for the central-MC4R framework, C1 for the FDA's MOA-unknown wording.

The route-of-administration history is the second important strand, because Palatin spent most of the 2000s developing intranasal bremelanotide for both male erectile dysfunction and female sexual dysfunction before pivoting to subcutaneous injection. The Diamond et al. 2004 International Journal of Impotence Research paper (PMID 14963471) is the readable phase-1/2 record of intranasal PT-141: dose-dependent erections in healthy men and Viagra-responsive ED patients above 7 mg, onset around 30 minutes, well tolerated within those studies but with flushing and nausea as the dominant adverse events. A 2005 Diamond Urology paper combined low-dose intranasal PT-141 with sildenafil in ED men and showed enhanced erectile response. The 2008 Safarinejad and Hosseini "Salvage of sildenafil failures with bremelanotide" study reported on intranasal PT-141 in 342 sildenafil non-responders with a positive efficacy signal, though this paper later received an Expression of Concern (PMID 36626345) and should be cited only with that caveat. What ended the intranasal program was not efficacy but cardiovascular safety. The intranasal route produced variable plasma levels and significant blood pressure increases in some subjects, the FDA placed clinical holds on the intranasal trials in 2007–2008, and Palatin reformulated as a subcutaneous autoinjector. The new route gave more reproducible kinetics and a more manageable blood-pressure profile, and it is the basis of the eventual Vyleesi approval. The men's-ED development program that followed was pursued in parallel for several years and ultimately did not produce an FDA-approved product for men; the company's later strategy moved toward bremelanotide-PDE5i co-formulations for PDE5i-non-responder ED and toward the female HSDD indication that did succeed. Sources: Diamond 2004 intranasal PT-141, PMID 14963471, Diamond 2005 PT-141 plus sildenafil, PMID 15833522, Safarinejad 2008 salvage of sildenafil failures, PMID 18206919, Expression of Concern, PMID 36626345, Bremelanotide Wikipedia development history. Confidence: C2 for the development arc and intranasal-to-subcutaneous pivot; C3 for the men's-ED program closure given that some details live in press releases rather than peer-reviewed papers.

The Vyleesi approval itself is what the user's draft mainly bears on, and the regulatory record is unambiguous. The FDA approved bremelanotide on June 21, 2019 under NDA 210557, and the agency's label is the dispositive document. The approved indication is "the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance." That language is narrower than "FDA-approved for libido enhancement" in three specific ways. First, the population is premenopausal women only; the label explicitly states that Vyleesi is not approved for postmenopausal women or for men, and an "Limitations of Use" subsection notes that effectiveness was not demonstrated in postmenopausal women. Second, the disorder is generalized HSDD, meaning low desire across situations and partners rather than partner- or situation-specific desire problems. Third, the disorder must be acquired rather than lifelong. Vyleesi is therefore licensed as a treatment for a specific DSM-style sexual desire disorder in a specific demographic, not as a general libido enhancer in any healthy adult who wants more interest in sex. Sources: Vyleesi prescribing information at DailyMed, FDA Vyleesi label PDF, FDA approval announcement, AMAG/Palatin press release. Confidence: C1.

The dose, route, and frequency from the label are precise enough to quote: 1.75 mg administered subcutaneously into the abdomen or thigh via a single-use autoinjector, no sooner than 45 minutes before anticipated sexual activity, with no more than one dose in any 24-hour period and no more than eight doses in any month. The label also instructs prescribers to discontinue Vyleesi if there is no improvement after eight weeks of use. The pharmacokinetics support the on-demand framing: subcutaneous bioavailability is approximately 100%, median Tmax is about 1.0 hour (range 0.5–1.0), the mean terminal half-life is approximately 2.7 hours (range 1.9–4.0), volume of distribution is about 25 L, clearance is about 6.5 L/hour, plasma protein binding is about 21%, and elimination is roughly 64.8% urinary and 22.8% fecal. The user's draft claim of a 2–4 hour half-life is therefore correct as a stated range and within the FDA's labeled distribution, although the central tendency is on the lower end of that band, around 2.7 hours. The on-demand window is best described as a roughly 6-to-10-hour pharmacological tail with the most concentrated central effect in the first hour or two. Sources: Vyleesi prescribing information at DailyMed, Bremelanotide Wikipedia pharmacokinetics summary. Confidence: C1.

The efficacy data from the RECONNECT phase-3 program are where rigour is most needed, because the marketing summary is much friendlier to bremelanotide than the underlying numbers are. Two identically designed, randomized, double-blind, placebo-controlled trials (Studies 301 and 302) enrolled a total of 1,267 premenopausal women with acquired generalized HSDD across U.S. sites; the efficacy population was 1,202. Treatment was 24 weeks of on-demand subcutaneous bremelanotide 1.75 mg or matching placebo. The two co-primary endpoints were the change from baseline in the Female Sexual Function Index–desire domain (FSFI-D) and the change from baseline on item 13 of the Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO), which asks specifically about distress about low sexual desire. Both endpoints were statistically significant for bremelanotide over placebo. The integrated improvement on FSFI-D was approximately 0.30 to 0.35 points (on a roughly 1.2 to 6.0 scale, p<0.001), and the integrated reduction on FSDS-DAO item 13 was approximately 0.29 to 0.37 points (on a 0 to 4 scale, p<0.001 to 0.005). The responder analysis using a dynamic anchor reported approximately 58% bremelanotide responders versus approximately 36% placebo responders across the two studies on FSFI-D, and the user's draft claim that "about 25% of women had a clinically meaningful response on the FSDS-DAO" is consistent with the more demanding distress-anchor responder analyses that have appeared in subsequent reviews and FDA briefing materials, though the precise percentage depends on which threshold the analyst uses. The placebo response is genuinely substantial and is one of the most important features of the dataset: women in HSDD trials respond to attention, structured assessment, and protocolized expectation-setting at high rates, which compresses the absolute drug-versus-placebo effect into a modest band. Sources: Kingsberg et al. 2019 Obstet Gynecol RECONNECT, PMID 31599840, RECONNECT integrated analysis PMC summary, Vyleesi efficacy HCP page. Confidence: C2 for the published numbers and the substantial placebo response framing.

Effect-size honesty is essential here. The drug works on average, but the average effect is small in absolute terms and indistinguishable for many individual women from no effect, while a smaller subset shows a clearly meaningful change. Reviewers comparing bremelanotide with flibanserin and with watchful-waiting interventions for HSDD generally land in the same place: a modest within-class improvement, a high-effort regulatory framework (REMS, prescriber education, label-specific contraindications), and a non-trivial side-effect cost. The honest framing is "useful for some women, modest for many, and unsuitable or inadequate for others," not "FDA-approved libido enhancer that reliably increases sex drive." Sources: Kingsberg et al. 2019, PMID 31599840, Simon et al. 2019 long-term safety/efficacy, PMID 31599847, MGH Center for Women's Mental Health summary. Confidence: C2.

The safety profile from the integrated phase-3 analysis is where bremelanotide pays for its central mechanism. The most common adverse events in the integrated double-blind data were nausea (40.0% bremelanotide vs 1.3% placebo; median onset around 30 minutes, median duration about 2.4 hours), flushing (20.3% vs 0.3–1.3%), headache (11.3% vs 1.9%), and injection site reactions (around 13% vs 0.5%); vomiting was approximately 4.8%. Discontinuation due to nausea specifically was 8.1% in the double-blind program. The total discontinuation rate due to adverse events in the open-label extension was substantially higher and varies by source: Clayton and colleagues' integrated safety review reports roughly 18.7% to 23.4% in the original-bremelanotide arms and around 24%–26% in the placebo-to-bremelanotide crossover groups during long-term follow-up, which justifies the user's draft framing of "about 18% discontinuation due to adverse events" as broadly correct for the long-term cohort and somewhat understated for the placebo-crossover group. The blood pressure signal is the safety feature that earned a labeled warning rather than just an adverse-event listing. Vyleesi causes a transient post-dose increase of approximately 6 mmHg systolic and 3 mmHg diastolic on average, with a parallel decrease in heart rate of about 5 bpm, peaking within roughly 2 hours and returning toward baseline within about 8–12 hours. Mean changes are small, but individual excursions can be much larger, which is why the label is explicit that Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease and is not recommended in patients at high cardiovascular risk. This contraindication framing is the chief difference between Vyleesi and PDE5 inhibitors as cardiovascular safety profiles: PDE5 inhibitors carry their own contraindication around concomitant nitrate use because of catastrophic hypotension, while Vyleesi carries the opposite contraindication because of transient hypertension. Sources: Vyleesi prescribing information at DailyMed, Clayton et al. 2022 safety profile, PMID 35147466, Bremelanotide LiverTox NIH NBK573221. Confidence: C1 for the labeled rates; C2 for the long-term-extension discontinuation numbers.

Focal hyperpigmentation deserves its own paragraph because it is the most distinctive bremelanotide adverse event and the one whose mechanism is most "interesting" in the user's sense. The label-quoted rate is approximately 1% in patients receiving up to eight doses per month, which matches the labeled monthly maximum, and the rate climbs steeply with daily or near-daily dosing. The Vyleesi label specifically reports that focal hyperpigmentation occurred in more than one-third (approximately 38%) of subjects who received up to 16 consecutive daily doses in dedicated dose-frequency studies, and the affected sites in published reports include the face, gingiva, areolae, and breasts. The mechanism is direct: bremelanotide is a structural constrained-cyclic analog of α-MSH, the natural ligand that activates MC1R on melanocytes to drive cAMP-mediated transcription of tyrosinase and the eumelanin synthesis pathway. The label's potency-order ranking explicitly lists MC1R first among bound receptors, which means residual MC1R agonism is part of bremelanotide's pharmacology even at the lowered MC1R activity that distinguishes it from MT-II. At label-compliant on-demand dosing the cumulative MC1R exposure stays low enough that pigmentation usually does not become clinically apparent, but daily or off-label dosing turns the same residual activity into visible pigmentation, especially in patients with darker skin who already have higher constitutive eumelanin. The user's framing of hyperpigmentation as a roughly 1-in-100 effect with an "interesting" pharmacological cause is therefore accurate at the labeled-dosing rate; the rate becomes meaningfully higher in real-world overdosing or daily-dosing scenarios. Sources: Vyleesi prescribing information at DailyMed, FDA Vyleesi label PDF, Clayton et al. 2022 safety profile, PMID 35147466. Confidence: C1.

Bremelanotide and PDE5 inhibitors really do live in different side-effect regimes, which means the user's draft claim that "PT-141 has more potential side effects than PDE5i" is approximately right but worth unpacking. PDE5 inhibitors at standard doses have a well-characterized profile dominated by headache (around 15%), flushing (around 10%), dyspepsia, nasal congestion, vision changes (cyanopsia for sildenafil, blue-tint), back pain (especially tadalafil), and rare but serious events (NAION, hearing loss, priapism, profound hypotension with concomitant nitrate). Bremelanotide has a higher rate of nausea than any common PDE5i adverse event, comparable flushing, comparable headache, plus injection-site effects and a labeled blood-pressure-elevation contraindication that PDE5 inhibitors do not carry. Discontinuation rates due to adverse events are also higher for bremelanotide in the long-term data than they typically are for PDE5 inhibitors. Mechanism explains this: PDE5 inhibitors only need to act on a peripheral enzymatic step, while melanocortin agonism reaches into autonomic, gastrointestinal, and pigmentary pathways simultaneously. Sources: Vyleesi prescribing information at DailyMed, Sildenafil prescribing information PDE5i comparator profile, Clayton 2022 safety review, PMID 35147466. Confidence: C2.

The other approved central-acting drug in the female HSDD space is flibanserin (Addyi), and the contrast with bremelanotide is the cleanest available illustration of how unrelated two HSDD drugs can be at the mechanism level. Flibanserin is a small-molecule serotonin-1A receptor full agonist and serotonin-2A receptor antagonist with additional 5-HT2B/2C and dopamine D4 activity, taken orally once daily at bedtime, and intended to shift the prefrontal-limbic balance toward dopaminergic and noradrenergic signalling consistent with reward and desire. Its effect size in trials was on the order of 0.5 additional satisfying sexual events per month and approximately 0.3 to 0.4 points on the relevant desire scale, similar in magnitude to bremelanotide's effect on FSFI-D. Its safety profile is dominated by hypotension, syncope, somnolence, and a black-boxed alcohol interaction (relaxed but still labeled). Bremelanotide is on-demand, subcutaneous, melanocortinergic, and carries hypertension/CV-risk contraindications instead. The two drugs therefore do similar amounts of clinical work through entirely different neurochemistry, with entirely different side-effect ceilings. The clinical decision between them is rarely a head-to-head efficacy decision; it is a route, dosing-pattern, and contraindication decision. Sources: Addyi (flibanserin) prescribing information PDF, Flibanserin StatPearls NIH NBK589649, Flibanserin and HSDD review, PMC5358680. Confidence: C1 for the mechanism summaries and dosing patterns.

Melanotan II must be considered separately because it is not the same regulatory or safety object as bremelanotide. MT-II has never been approved by the FDA or by EMA for any indication. It is sold online as research-grade lyophilized powder, often imported from gray-market suppliers, and used by consumers primarily for tanning and secondarily for libido. The first regulatory consequence is purity: independent analyses of online-sourced peptide vials have repeatedly shown wide variation in actual peptide content, contamination with bacterial endotoxin, presence of unrelated peptides, and underdosing or overdosing relative to label, none of which a buyer can verify at home. The second regulatory consequence is dose: with no validated dosing schedule and no autoinjector, MT-II users typically self-administer subcutaneous doses ranging from a few hundred micrograms to several milligrams depending on internet protocols, and the dose-response curve for MC1R-mediated pigmentation, MC4R-mediated libido, and the off-target consequences is steep. The case-report literature has accumulated several distinct flavours of harm: melanocytic concerns, with case reports of melanoma diagnosed during or shortly after MT-II use including a 20-year-old woman with a histologically confirmed melanoma in a previously inconspicuous gluteal lesion (Cardones and Grichnik 2014, PMID 24355990); systemic sympathomimetic toxicity with rhabdomyolysis and acute kidney injury after a 6 mg dose roughly six times typical starting amounts (Nelson et al. 2012, PMID 23121206); priapism case reports (PMID 23537392); and a Swedish case of renal infarction in a 45-year-old man after cumulative 27 mg over six months (PMC7148395). The melanoma question deserves explicit caution: case reports cannot establish causality, the underlying epidemiology of melanoma in young tanning-bed users is already non-trivial, and constitutive MC1R activation in animal models has shown tumorigenic potential that is biologically plausible without being individually predictive. The right framing is that MT-II is a non-FDA-approved peptide of unknown purity with documented serious case reports and a biologically plausible long-term melanoma signal, not that everyone who uses MT-II will develop melanoma. Sources: Cardones & Grichnik 2014 melanoma case report, PMID 24355990, Nelson et al. 2012 rhabdomyolysis, PMID 23121206, Melanotan II priapism case, PMID 23537392, Renal infarction Swedish case, PMC7148395, DermNet NZ Melanotan II overview. Confidence: C2 for the case-report inventory and the framing.

The user's draft framing that MT-II "was found to raise libido and inspired the discovery of PT-141" is correct as historical sequence: the Wessells 1998/2000 papers established the libido signal in MT-II first, and Palatin's PT-141 program was explicitly a structure-activity-guided attempt to keep that signal while shifting the receptor potency away from MC1R, with the further consequence that the C-terminal-modified analog has more reproducible pharmacokinetics and a cleaner regulatory path. That story is now told in essentially the same form by Hadley and Dorr's 2006 review (PMID 16412534) and by the Palatin development summaries. Sources: Hadley & Dorr 2006, PMID 16412534, King et al. 2005, PMID 15996790, Wessells 2000 IJIR, PMID 11035391. Confidence: C2.

The user's recommendation that "if a user wants to use either, they should use PT-141" deserves to be stated more carefully. The two compounds are not interchangeable in any regulatory or safety sense. Bremelanotide as Vyleesi is an FDA-approved drug with a specific indication, a specific autoinjector, a specific manufactured dose, a defined pharmacokinetic envelope, and a labeled contraindication and warning structure. Melanotan II is an unapproved gray-market peptide with no quality controls, no validated dose, accumulating case-report harms, and a plausible long-term skin-cancer signal. If the user means "as between MT-II and bremelanotide for someone seeking a melanocortin-mediated libido effect, bremelanotide is the only defensible choice," that is correct and consistent with the mainstream dermatology and sexual-medicine literature. If the user means "both are acceptable and bremelanotide is just preferred," that is not a defensible reading of the safety data. MT-II is not an acceptable substitute for bremelanotide for a libido indication; it is a compound that happens to have similar central pharmacology along with substantially worse off-target activity and substantially worse manufacturing controls, and using it in place of an FDA-approved product to obtain a labeled effect is not endorsed by any reputable clinical source. The user's draft also correctly excludes the use of MT-II off-label for libido. The honest version of the user's recommendation is something closer to: "If you are considering either of these melanocortin agonists for libido, only bremelanotide (Vyleesi) has the regulatory and manufacturing record to be defensible, and it should be evaluated against PDE5 inhibitors and against flibanserin within its FDA-approved population, with the contraindication and side-effect profile fully internalized." Sources: Vyleesi prescribing information at DailyMed, DermNet NZ Melanotan II overview, Westlake Dermatology MT-II safety summary. Confidence: C2 for the recommendation reframing.

A few additional points belong in any rigorous treatment of this pathway because they routinely get blurred in popular writeups. The first is that bremelanotide is not approved for men, and the men's-ED development program never converted into an approved product despite over a decade of sustained work. The Diamond, Safarinejad, and combination-with-sildenafil studies showed real signals but were either intranasal (and shut down for cardiovascular reasons) or required combination strategies that the FDA did not credit as a free-standing efficacy story. The 2008 Safarinejad sildenafil-non-responder study was later flagged with an Expression of Concern and should be read with that caveat. The most defensible current statement about men is that bremelanotide has plausible biological activity for ED and low desire in men but no FDA-approved men's indication, and the off-label market that has grown around compounded peptide bremelanotide for men is operating in a space where the regulatory and safety frame is much weaker than it is for the approved Vyleesi premenopausal-HSDD use. Sources: Diamond 2004 intranasal PT-141, PMID 14963471, Safarinejad 2008, PMID 18206919, Expression of Concern, PMID 36626345, Diamond 2005 PT-141 plus sildenafil, PMID 15833522. Confidence: C2.

The second is that the cardiovascular signal in bremelanotide trials is not just about average mmHg changes. The label warns specifically against use in patients with uncontrolled hypertension or known cardiovascular disease, and the mean systolic increase of about 6 mmHg with a peak around 2 hours hides individual excursions that can be larger and that, in a patient with poorly controlled baseline blood pressure or unrecognized coronary disease, are the kind of pharmacologic perturbation that creates a low-frequency but real adverse-event tail. The original intranasal program was shut down precisely because plasma levels were too variable and the blood-pressure signal too unpredictable to sustain a development program. The subcutaneous reformulation made the kinetics more reproducible, but it did not abolish the underlying vasoactive effect, which is why the contraindication is on the label. Sources: Vyleesi prescribing information at DailyMed, Bremelanotide Wikipedia development history, Clayton 2022 safety review, PMID 35147466. Confidence: C2.

The third is that the responder narrative around bremelanotide deserves to be read with explicit attention to placebo response. Approximately 36% of placebo-arm women in RECONNECT met the dynamic-anchor responder threshold on FSFI-D. Approximately 58% of bremelanotide-arm women did. The drug-placebo difference, around 22 percentage points, is the real signal. That is a meaningful effect at the population level and a clearly small effect at the individual level, and the difference matters for how patients should be counseled: a substantial fraction of women reporting benefit on bremelanotide would have reported benefit on placebo through a structured assessment-and-attention pathway alone, and the marginal contribution of the drug is the part that has to justify the side-effect cost and the on-demand injection burden. Sources: Kingsberg et al. 2019 RECONNECT, PMID 31599840, RECONNECT integrated analysis PMC summary. Confidence: C2.

The fourth is that the FDA review captured several specific concerns that the user's draft does not fully reflect. The agency concluded that bremelanotide met its prespecified efficacy endpoints, but it also imposed a Vyleesi-specific REMS-style prescriber-education framework, the cardiovascular contraindication, the focal-hyperpigmentation warning, and the explicit eight-doses-per-month and one-dose-per-24-hour ceilings precisely because the risk-benefit balance is narrow. The label's "Limitations of Use" subsection is unusually direct about what Vyleesi is not: it is not approved to enhance sexual performance, it is not approved for postmenopausal women, and it is not approved for men. The draft framing of "FDA-approved for libido enhancement" therefore needs to be replaced with a more accurate "FDA-approved for acquired generalized HSDD in premenopausal women, with explicit limitations of use." Sources: Vyleesi prescribing information at DailyMed, FDA Vyleesi label PDF. Confidence: C1.

Pulling the strands together, the melanocortin libido pathway is one of the more interesting central mechanisms in modern sexual pharmacology, and it has produced exactly one FDA-approved drug (bremelanotide for premenopausal acquired generalized HSDD) and exactly one widely used unregulated counterpart (Melanotan II, sold for tanning and used off-label for libido). The two compounds share a structural lineage, a discovery story rooted in University of Arizona phase-1 work, and a centrally-mediated effect on sexual motivation that PDE5 inhibitors cannot replicate. They differ in regulatory status, manufacturing controls, receptor selectivity, route, dose discipline, and accumulated case-report harm. A reader writing about the pathway for a general audience can stay accurate by saying that bremelanotide is approved, narrowly indicated, modestly effective, side-effect-laden, and contraindicated in cardiovascular disease, while Melanotan II is unapproved, of unknown purity, plausibly libido-active by virtue of the same machinery, and carries case-report harms that go well beyond bremelanotide's labeled adverse-event profile. The reader who wants more than that needs the FDA label, the RECONNECT papers, the Wessells trials, the Hadley-Dorr review, and the Clayton safety review, all of which are linked above and which together provide enough primary substrate to evaluate any claim about the pathway against the actual record. Sources: Vyleesi prescribing information at DailyMed, Kingsberg 2019 RECONNECT, PMID 31599840, Wessells 1998 J Urol, PMID 9679884, Wessells 2000 IJIR, PMID 11035391, Hadley & Dorr 2006, PMID 16412534, Clayton 2022, PMID 35147466. Confidence: C1-C2.

Verdict on Each Draft Claim

1. "Bremelanotide/PT-141 is FDA-approved for libido enhancement." KIND-OF-TRUE. The FDA approved Vyleesi (bremelanotide) on June 21, 2019, but the indication is narrow: treatment of premenopausal women with acquired, generalized HSDD. The label explicitly excludes postmenopausal women, men, and "enhancement of sexual performance" use. Calling it "FDA-approved for libido enhancement" is too broad. Source: Vyleesi prescribing information.

1. "PT-141 is used to treat low sexual desire in women (HSDD)." TRUE, with the qualification that the approved population is premenopausal acquired generalized HSDD only. Source: FDA Vyleesi label.

1. "PT-141 is typically administered by injection." TRUE. The approved formulation is a 1.75 mg subcutaneous autoinjector for the abdomen or thigh. Earlier intranasal formulations were dropped because of variable kinetics and blood-pressure problems. Source: Vyleesi prescribing information.

1. "PT-141 elimination half-life is reported to be 2–4 hours." TRUE. The FDA label gives a mean terminal half-life of approximately 2.7 hours with a range of 1.9–4.0 hours, which falls within the 2–4 hour stated band. Source: Vyleesi prescribing information.

1. "PT-141 effects can be useful or modest depending on the person." TRUE. The RECONNECT trials show a small average effect size with a substantial placebo response and a meaningful but minority responder group; some women experience clear benefit and others experience little or none. Source: Kingsberg 2019, PMID 31599840.

1. "PT-141 has more potential side effects than PDE5i." KIND-OF-TRUE. The total adverse-event load (nausea around 40%, flushing around 20%, headache around 11%, injection-site reactions around 13%, focal hyperpigmentation, transient hypertension, contraindication in CV disease) is qualitatively heavier than the standard PDE5i profile (headache around 15%, flushing around 10%, dyspepsia, vision changes, rare NAION/priapism, contraindication with nitrates). The framing is correct in direction but obscures the fact that PDE5i side effects are not trivial either. Sources: Vyleesi prescribing information, Sildenafil prescribing information.

1. "Hyperpigmentation is a rare (~1 in 100) side effect for interesting reasons." TRUE. The FDA label reports focal hyperpigmentation in approximately 1% of patients receiving up to eight doses per month and approximately 38% with up to 16 consecutive daily doses. The mechanism is residual MC1R agonism, since bremelanotide is a structural α-MSH analog and α-MSH/MC1R signalling drives eumelanin synthesis. The user's "interesting reasons" framing is correct. Source: Vyleesi prescribing information.

1. "Melanotan II is a peptide used to increase melanin production in skin." TRUE. MT-II is an unapproved cyclic-heptapeptide α-MSH analog used primarily for cosmetic tanning via MC1R activation, with libido as a secondary off-label use. Source: DermNet NZ Melanotan II.

1. "Melanotan II was found to raise libido and inspired the discovery of PT-141." TRUE. The Wessells 1998 J Urol study (PMID 9679884) and Wessells 2000 IJIR study (PMID 11035391) established the libido and erectile signal in MT-II at the University of Arizona, and PT-141 was developed by Palatin Technologies as a C-terminal-modified analog optimized for central libido effect with reduced MC1R activity. Sources: Wessells 1998, PMID 9679884, Hadley & Dorr 2006, PMID 16412534.

1. "If a user wants to use either, they should use PT-141 (not Melanotan II)." TRUE in direction, but the framing should be tightened. The right statement is that bremelanotide (Vyleesi) is the only defensible choice between the two for any libido use case because it is FDA-approved, has a known dose, validated kinetics, manufacturer quality controls, and a documented adverse-event profile; Melanotan II is unapproved, of unknown purity, and has documented case reports of melanoma, rhabdomyolysis, renal infarction, and priapism. Saying "if you want to use either, use PT-141" understates the gap; a more honest version is "do not use MT-II, and consider bremelanotide only within its FDA-approved indication and contraindication framework." Sources: Cardones & Grichnik 2014 melanoma case, PMID 24355990, Nelson 2012 rhabdomyolysis, PMID 23121206, Vyleesi prescribing information.